TOSEDOSTAT is an oral aminopeptidase inhibitor that has demonstrated anti -tumour response in blood cancers and solid tumours in phase 1-2 clinical trials .At present, phase 2/3 is being conducted referred to as AML less intensive(LI-D trial).
Aminopeptidases are required by tumour cells to provide amino acids necessary for growth and survival .
Tosedostat is curently being evaluated in multiple phase 2 trials for treatment of patients with Acute Myeloid Leukemia(AML) or high risk Myelodysplastic Syndrome(MDS)
Aminopeptidases are required by tumour cells to provide amino acids necessary for growth and survival .
Tosedostat is curently being evaluated in multiple phase 2 trials for treatment of patients with Acute Myeloid Leukemia(AML) or high risk Myelodysplastic Syndrome(MDS)